Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Parallel, Open-label, Multicenter, Positive-controlled, Superiority Phase III Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly

NCT07623824 is registered in ClinicalTrials.gov with CSPC ZhongQi Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT07623824
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07623824 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Parallel, Open-label, Multicenter, Positive-controlled, Superiority Phase III Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly
Lead sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
May 31, 2026
Completion date
December 30, 2029
Enrollment
154 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diagnosed with acromegaly, currently in the active stage of the disease